Speech is emerging as a scalable, non-invasive biomarker in diagnostics, particularly for neurodegenerative conditions such as Alzheimer’s disease and Parkinson’s disease. Subtle changes in voice, language, and fluency—captured via simple recordings and analyzed with AI—enable early detection and continuous, real-world monitoring. This is a startup-led category, with companies like Aural Analytics, Winterlight Labs, Kintsugi, Calliope, Thymia, and Canary Speech building software-first solutions, alongside ecosystem initiatives such as SpeechDx and Bridge2AI that are accelerating validation and standardization. Together, these efforts point to a clear commercialization path across clinical screening, remote monitoring, and pharmaceutical trials, where speech-based endpoints can improve patient stratification and enable more scalable, continuous assessment. Lampros is moderating a panel discussion on voice biomarkers and their emerging role in neurological diseases at the 2025 Bridge2AI Symposium in Tampa.
